EyePoint Pharmaceuticals, Inc. reported its financial outcomes for the fourth quarter and full year ended December 31, 2023, on March 7, 2024. The company announced significant progress in its clinical trials, including positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, which met all primary and secondary endpoints. The initiation of the first Phase 3 clinical trial for EYP-1901 is expected in the second half of 2024. EyePoint also dosed the first patient in the Phase 2 VERONA trial for diabetic macular edema (DME), with topline data expected in the first quarter of 2025. Additionally, topline data from the Phase 2 PAVIA trial in NPDR is anticipated in the second quarter of 2024. The company appointed Dr. Ramiro Ribeiro as Chief Medical Officer...Show More

EyePoint Pharmaceuticals, Inc. reported its financial outcomes for the fourth quarter and full year ended December 31, 2023, on March 7, 2024. The company announced significant progress in its clinical trials, including positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, which met all primary and secondary endpoints. The initiation of the first Phase 3 clinical trial for EYP-1901 is expected in the second half of 2024. EyePoint also dosed the first patient in the Phase 2 VERONA trial for diabetic macular edema (DME), with topline data expected in the first quarter of 2025. Additionally, topline data from the Phase 2 PAVIA trial in NPDR is anticipated in the second quarter of 2024. The company appointed Dr. Ramiro Ribeiro as Chief Medical Officer and reported a strong financial position with $331 million in cash and investments as of December 31, 2023. This financial stability is expected to fund operations through the topline data of Phase 3 trials for EYP-1901 for wet AMD in 2026. Total net revenue for the fourth quarter was $14.0 million, a significant increase from the previous year's quarter. The company also completed an upsized underwritten public offering, raising $230 million in December. EyePoint's shares are traded on the Nasdaq Global Market under the symbol EYPT.